Liver cancer drug combo gets its second FDA rejectionnews2025-03-21T22:28:58+00:00March 21st, 2025|Endpoints News|
Alnylam hopes its ATTR-CM label will give Amvuttra an edgenews2025-03-21T18:50:43+00:00March 21st, 2025|Endpoints News|
FDA approves Novartis’ Fabhalta in C3 glomerulopathynews2025-03-21T15:38:57+00:00March 21st, 2025|Endpoints News|
FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBionews2025-03-20T21:40:37+00:00March 20th, 2025|Endpoints News|
Akero exec calls MASH accelerated approval guidance ‘bizarre’news2025-03-20T19:41:09+00:00March 20th, 2025|Endpoints News|
Many rare disease drugs rely on just one trial for approval, FDA authors findnews2025-03-20T19:38:52+00:00March 20th, 2025|Endpoints News|
Trump’s DOJ rejects effort to shed mifepristone restrictionsnews2025-03-19T17:20:32+00:00March 19th, 2025|Endpoints News|
Ahead of FDA decision, Alnylam faces the big question: Can it make money?news2025-03-19T15:24:19+00:00March 19th, 2025|Endpoints News|
FDA staff return to White Oak campus after Trump administration pushnews2025-03-17T20:02:36+00:00March 17th, 2025|Endpoints News|
